Mats-Olof Wallin
Director of Finance/CFO at OxThera AB
Mats-Olof Wallin active positions
Companies | Position | Start | End |
---|---|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Director of Finance/CFO | 31/12/2019 | - |
Career history of Mats-Olof Wallin
Former positions of Mats-Olof Wallin
Companies | Position | Start | End |
---|---|---|---|
KARO PHARMA AB (PUBL) | Director of Finance/CFO | 31/12/2017 | 30/09/2019 |
SWEDISH ORPHAN BIOVITRUM AB | Director of Finance/CFO | 07/04/2013 | 19/07/2018 |
BIOTAGE AB | Director of Finance/CFO | 16/05/2010 | 31/12/2011 |
Public Communications Contact | 16/05/2010 | 31/12/2011 |
Training of Mats-Olof Wallin
University of Uppsala | Undergraduate Degree |
Statistics
International
Sweden | 6 |
Operational
Director of Finance/CFO | 4 |
Public Communications Contact | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 3 |
---|---|
BIOTAGE AB | Health Technology |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
KARO PHARMA AB (PUBL) | Health Technology |
Private companies | 1 |
---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
- Stock Market
- Insiders
- Mats-Olof Wallin
- Experience